secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortrea Holdings Inc. (FTRE)
CIK:        0001965040
Form:       8-K
Filed at:   2025-06-11T23:59:59+00:00
Accession:  0001193125-25-139161
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortrea names Anshul Thakral as permanent CEO effective August 4, 2025
----------------------------------------------------------------------

- Anshul Thakral appointed President and CEO, effective August 4, 2025; replaces interim CEO Peter Neupert who remains chairman.
- Thakral has over 20 years experience in CRO, pharma, and biotech; Co-founder/CEO of Launch Therapeutics since 2022.
- Offer letter includes $1.1M base salary, 150% target bonus, and inducement equity grants of ~$12.5M (RSUs+PSAs) tied to performance.
- Thakral also appointed Class III director; his term expires at 2026 annual meeting.
- Severance plan amended to include CEO; equity grants outside 2023 Omnibus Incentive Plan (Nasdaq inducement exception).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1965040/000119312525139161/0001193125-25-139161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1965040/000119312525139161/d55989d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-139161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer